• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Korea·Healthcare·214450.KQ
Share

PharmaResearch Co., Ltd. Stocks

₩ 323500Last Updated 23.09.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

₩ 2.45B

₩ 323500
Key Takeaways

Risk factor

Good trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly patients; PLACENTEX injection for the treatment and tissue restoration of wounds; CLEVIEL VOLUME to temporarily improve facial wrinkles in adults through the physical restoration; Rejuran HB plus which is used for temporary improvement of adult's crow's feet wrinkles; Rejuvenex injection, a tissue regeneration activator that regenerates connective tissues, including ligament, tendon, skin, etc.; and Rejuvenex cream, which treats the wound through rapid tissue regeneration. It also provides REJURAN, a medical device for face (especially eye, perioral area), neck, Décolleté, hands, etc; CLEVIEL prime plus and contour plus with lidocaine medical devices; D+CELL 350 TRA I; and REJURAN moisturizer for daily skin protection, as well as REJUVENEX SCULPT V; REJURAN concentrate for sensitive and aged skin; REJURAN healing eye gel and mask; REJURAN sunscreen that protects skin from UV rays; and REJURAN recover soothing mask. In addition, the company offers D+CELL 350 TRA concentrated rejuvenation cream, intensive repair serum, activating facial toner, high potency eye lift, moisture balancer, mask, hair, cream, and hydro products; REJURAN tone-up booster; REJURAN FORTE; and CONJURAN medical devices. Further, it offers functional foods; and engages in the development of software and consulting businesses. The company was formerly known as Pharma Research Products Co., Ltd. and changed its name to PharmaResearch Co., Ltd. in April 2021. PharmaResearch Co., Ltd. was founded in 1993 and is headquartered in Gangneung-si, South Korea.

Company Valuation

Slightly overvalued
3/7

Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA,

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 214450.KQ is 517467 and suggests 59.7% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

23.09.2026 14:28

Is the small-cap rally coming to an end? 4 rules for picking stocks as the Fed raises rates

23.09.2026 14:02

Shares of Chinese AI developers fell following reports of an investigation into DeepSeek and Moonshot

23.09.2026 13:32

Apollo has restricted withdrawals from its private lending fund for the third consecutive time

23.09.2026 13:01

The crisis involving investment funds in Turkey is not over yet. What should investors keep an eye on?

23.09.2026 12:31

Oil is heading for its longest losing streak of the year. Traders' bets on a decline are at a peak.

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026